Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled TrialsMegan E. B. Clowse, Daniel J. Wallace, Richard Furie et al.|Arthritis & Rheumatology|2016Cited by 237